Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN smallpox vaccine in children from birth to less than 12 years of age.

Trial Profile

Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN smallpox vaccine in children from birth to less than 12 years of age.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2014

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Therapeutic Use
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 30 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top